- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, discusses the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
SGLT2 inhibitors simplify treatment due to their fixed dose, minimal side effects, and ease of combination with existing medications.
In addition, many doctors are familiar with these drugs as they are commonly used for diabetes and kidney problems.
“The SGLT2 inhibitors have actually been a remarkable success and a remarkable addition to the armamentarium of available therapies and Heart failure,” Muthu said.
Muthu Vaduganathan Gives Insights on the Cost Effectiveness of SGLT2 Inhibitors
March 29th 2024In this second part of a two-part video series, MHE editors spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the cost effectiveness of SGLT2 inhibitors.
Read More
Stephen Greene, MD, Gives Insight on the New Heart Failure Drug Sotagliflozin
February 20th 2024Stephen Greene, MD, of Duke University School of Medicine, explains that Inpefa (sotagliflozin), a recently FDA-approved dual SGLT-1 and SGLT-2 inhibitor, aims to reduce cardiovascular death, heart failure, hospitalizations, or urgent heart failure visits among patients with heart failure, chronic kidney disease, type 2 diabetes, and another cardiovascular risk factor.
Read More
